Nuhad K. Ibrahim

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier, Charles M. Perou, W. Fraser Symmans et al. · Clinical Cancer Research · 2005 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +17

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar, Nuhad K. Ibrahim, Deborah Francis et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

Kenneth R. Hess, K. Anderson, W. Fraser Symmans et al. · Journal of Clinical Oncology · 2006 · 728 citations

Medicine, Oncology, Pharmacology +13

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Nuhad K. Ibrahim, Neil Desai, Sewa S. Legha et al. · PubMed · 2002 · 630 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Mark Ayers, W. Fraser Symmans, James Stec et al. · Journal of Clinical Oncology · 2004 · 569 citations

Medicine, Cancer Biology, Oncology +17